» Articles » PMID: 15453709

Induction of Apoptosis by Shikonin Through Coordinative Modulation of the Bcl-2 Family, P27, and P53, Release of Cytochrome C, and Sequential Activation of Caspases in Human Colorectal Carcinoma Cells

Overview
Date 2004 Sep 30
PMID 15453709
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Shikonin is a main constituent of the roots of Lithospermum erythrorhizon that has antimutagenic activity. However, its other biological activities are not well-known. Shikonin displayed a strong inhibitory effect against human colorectal carcinoma COLO 205 cells and human leukemia HL-60 cells, with estimated IC(50) values of 3.12 and 5.5 microM, respectively, but were less effective against human colorectal carcinoma HT-29 cells, with an estimated IC(50) value of 14.8 microM. Induce apoptosis was confirmed in COLO 205 cells by DNA fragmentation and the appearance of a sub-G1 DNA peak, which were preceded by loss of mitochondrial membrane potential, reactive oxygen species (ROS) generation, cytochrome c release, and subsequent induction of pro-caspase-9 and -3 processing. Cleavages of poly(ADP-ribose) polymerase (PARP) and DNA fragmentation factor (DFF-45) were accompanied by activation of caspase-9 and -3 triggered by shikonin in COLO 205 cells. Here, we found that shikonin-induced apoptotic cell death was accompanied by upregulation of p27, p53, and Bad and down-regulation of Bcl-2 and Bcl-X(L), while shikonin had little effect on the levels of Bax protein. Taken together, we suggested that shikonin-induced apoptosis is triggered by the release of cytochrome c into cytosol, procaspase-9 processing, activation of caspase-3, degradation of PARP, and DNA fragmentation caused by the caspase-activated deoxyribonuclease through the digestion of DFF-45. The induction of apoptosis by shikonin may provide a pivotal mechanism for its cancer chemopreventive action.

Citing Articles

Pharmacological Significance of with Special Insights into Shikonin and Its Potential in the Food Industry.

Gautam S, Lapcik L, Lapcikova B Foods. 2024; 13(9).

PMID: 38731721 PMC: 11082953. DOI: 10.3390/foods13091350.


Anoikis and cancer cell differentiation: novel modes of shikonin derivatives anticancer action in vitro.

Bovan D, Krajnovic T, Vukovic N, Vukic M, Mijatovic S, Tanic N Mol Biol Rep. 2024; 51(1):218.

PMID: 38281240 DOI: 10.1007/s11033-023-09093-x.


Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?.

Brockmueller A, Buhrmann C, Moravejolahkami A, Shakibaei M J Adv Res. 2024; 66:181-195.

PMID: 38190940 PMC: 11674784. DOI: 10.1016/j.jare.2024.01.005.


The anti-leukemia activity and mechanisms of shikonin: a mini review.

Dong H, Chang C, Gao F, Zhang N, Yan X, Wu X Front Pharmacol. 2023; 14:1271252.

PMID: 38026987 PMC: 10651754. DOI: 10.3389/fphar.2023.1271252.


Characterization of a small-molecule inhibitor targeting NEMO/IKKβ to suppress colorectal cancer growth.

Yu Z, Gao J, Zhang X, Peng Y, Wei W, Xu J Signal Transduct Target Ther. 2022; 7(1):71.

PMID: 35260565 PMC: 8904520. DOI: 10.1038/s41392-022-00888-1.